• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Hero Background
    English
    Chinese
    French
    Japanese
    Korean
    German
    Spanish

    Adrenocortical Carcinoma Treatment Market Trends

    ID: MRFR/Pharma/5105-HCR
    100 Pages
    Rahul Gotadki
    October 2025

    Adrenocortical Carcinoma Treatment Market Research Report Information By Type (Localized Adrenocortical Carcinoma, Metastatic Adrenocortical Carcinoma), Therapy (Radiation Therapy and Others), End-User (Hospitals and Clinics and Others) -Forecast till 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Adrenocortical Carcinoma Treatment Market Infographic
    $ 4,950.0
    $ 5,950.0
    $ 7,250.0

    Market Trends

    Key Emerging Trends in the Adrenocortical Carcinoma Treatment Market

    Huge steps in innovative work are forming the scene of ACC treatment. Drug organizations are putting vigorously in creative treatments and designated drugs, expecting to address the difficulties presented by Adrenocortical Carcinoma. These movements hold guarantee for more powerful and customized treatment regimens. Immunotherapy is arising as a unique advantage in cancer treatment, and the ACC market is no exemption. Progressing clinical preliminaries are investigating the capability of immunotherapeutic ways to deal with reinforce the body's safe reaction against ACC cells. The possibility of immunotherapy giving a more supportable and less intrusive treatment choice is filling market confidence. Fitting treatments to individual patients considering their hereditary cosmetics is acquiring noticeable quality in the ACC market. The approach of accuracy medication considers more designated treatments, limiting secondary effects and improving treatment viability. Microscopic profiling and hereditary testing are becoming basic parts of the ACC treatment venture. Aside from headways, challenges endure in the convenient determination and accessibility of ACC treatments. The uncommonness of Adrenocortical Carcinoma frequently prompts deferred analyze, influencing the general forecast. Furthermore, accessibility to state-of-the-art treatments stays a worry, particularly in districts with restricted medical services assets. Perceiving the significance of all-encompassing consideration, there is a developing accentuation on persistent promotion and backing programs. These drives intend to engage ACC patients with data, daily reassurance, and assets to explore their treatment process. The consideration of patient points of view in the improvement of new treatments is turning into an imperative pattern. Changes in medical care strategies and repayment systems are impacting the ACC treatment market. The acknowledgment of Adrenocortical Carcinoma as a rare infection and resulting strategy changes are working with better monetary help for patients, empowering innovative work, and upgrading in general market elements.

    Market Summary

    The Global Adrenocortical Carcinoma Treatment Market is projected to grow significantly from 3.82 USD Billion in 2024 to 8.85 USD Billion by 2032.

    Key Market Trends & Highlights

    Global Adrenocortical Carcinoma Treatment Key Trends and Highlights

    • The market is expected to experience a compound annual growth rate (CAGR) of 7.94 percent from 2025 to 2032.
    • By 2035, the market valuation is anticipated to reach 8.85 USD Billion, indicating robust growth potential.
    • In 2024, the market is valued at 3.82 USD Billion, reflecting the current demand for effective treatment options.
    • Growing adoption of advanced treatment modalities due to increasing awareness of adrenocortical carcinoma is a major market driver.

    Market Size & Forecast

    2024 Market Size 3.82 (USD Billion)
    2035 Market Size 8.85 (USD Billion)
    CAGR (2025-2035) 7.94%
    Largest Regional Market Share in 2024 latin_america)

    Major Players

    Arqule, Pfizer Ltd., EnGeneIC Ltd, Exelixis, Inc., Millendo Therapeutics, Inc., Merck & Co., Orphagen Pharmaceuticals, Inc., HRA Pharma, Bristol-Myers Squibb Company, General Electric Company, WG Critical Care, LLC, Mylan N.V., Fresenius Kabi AG, Sinovision Technologies (Beijing) CO., Ltd., Hitachi, Ltd., NeuroLogica Corp., Digirad Corporation

    Market Trends

    The ongoing advancements in therapeutic strategies for adrenocortical carcinoma treatment appear to enhance patient outcomes and may reshape the landscape of oncology care.

    National Cancer Institute

    Adrenocortical Carcinoma Treatment Market Market Drivers

    Rising Healthcare Expenditure

    The Global Adrenocortical Carcinoma Treatment Market Industry is also benefiting from increasing healthcare expenditure across various regions. Governments and private sectors are investing more in healthcare infrastructure, which facilitates better access to advanced cancer treatments. For instance, countries with robust healthcare systems are allocating significant budgets for oncology, thereby enhancing the availability of cutting-edge therapies for ACC. This trend is expected to drive market growth as more patients gain access to necessary treatments. The anticipated market value of 3.82 USD Billion in 2024 reflects this growing investment in healthcare.

    Emergence of Personalized Medicine

    The emergence of personalized medicine is reshaping the Global Adrenocortical Carcinoma Treatment Market Industry. Tailoring treatment plans based on individual genetic profiles and tumor characteristics allows for more effective and targeted therapies. This approach not only enhances treatment efficacy but also minimizes adverse effects, leading to improved patient satisfaction. As research continues to uncover the genetic underpinnings of ACC, the integration of personalized medicine into treatment protocols is expected to gain momentum. This trend aligns with the overall growth of the market, which is projected to reach 8.85 USD Billion by 2035.

    Advancements in Treatment Modalities

    Innovations in treatment modalities are significantly influencing the Global Adrenocortical Carcinoma Treatment Market Industry. The development of targeted therapies and immunotherapies has shown promise in improving patient outcomes. For instance, the introduction of drugs such as mitotane and novel immunotherapeutic agents has provided new avenues for treatment. These advancements not only enhance survival rates but also reduce the side effects associated with traditional therapies. As these treatment options become more widely available, the market is likely to witness substantial growth, with a projected compound annual growth rate (CAGR) of 7.94% from 2025 to 2035.

    Growing Awareness and Education Initiatives

    Growing awareness and education initiatives regarding adrenocortical carcinoma are playing a crucial role in the Global Adrenocortical Carcinoma Treatment Market Industry. Organizations and healthcare providers are increasingly focusing on educating both the public and healthcare professionals about the signs and symptoms of ACC. This heightened awareness leads to earlier diagnosis and treatment, which is essential for improving patient outcomes. As more individuals become informed about ACC, the demand for effective treatment options is likely to rise, contributing to the market's projected growth trajectory.

    Increasing Incidence of Adrenocortical Carcinoma

    The Global Adrenocortical Carcinoma Treatment Market Industry is experiencing growth due to the rising incidence of adrenocortical carcinoma (ACC). Recent statistics indicate that ACC is a rare but aggressive cancer, with an estimated annual incidence of 0.5 to 2 cases per million people. As awareness increases and diagnostic techniques improve, more cases are being identified, leading to a greater demand for effective treatment options. This trend is expected to contribute to the market's expansion, with projections indicating a market value of 3.82 USD Billion in 2024, potentially reaching 8.85 USD Billion by 2035.

    Market Segment Insights

    Regional Insights

    Key Companies in the Adrenocortical Carcinoma Treatment Market market include

    Industry Developments

    Future Outlook

    Adrenocortical Carcinoma Treatment Market Future Outlook

    The Global Adrenocortical Carcinoma Treatment Market is projected to grow at a 7.94% CAGR from 2024 to 2032, driven by advancements in targeted therapies and increasing awareness.

    New opportunities lie in:

    • Develop personalized treatment plans leveraging genomic profiling.
    • Invest in innovative drug delivery systems to enhance efficacy.
    • Expand clinical trial networks to accelerate drug approvals.

    By 2035, the market is expected to achieve substantial growth, reflecting enhanced treatment options and improved patient outcomes.

    Market Segmentation

    Intended Audience

    • Academic institutes and universities
    • Government research institutes
    • Diagnostic laboratories
    • Research and Development (R&D) companies
    • Oncology research institutes
    • Pharmaceutical companies

    Adrenocortical Carcinoma Treatment Market, by Type

    • Metastatic Adrenocortical Carcinoma
    • Localized Adrenocortical Carcinoma
    • Others
    • Adjuvant Therapy
    • Brachytherapy
    • External beam radiation therapy
    • Radiation Therapy
    • Targeted Therapy
    • Chemotherapy
    • Open surgery
    • Laparoscopic surgery
    • Surgery
    • Cancer Research Institutes
    • Ambulatory Surgical Centers
    • Hospitals and Clinics
    • Americas
    • North America
    • US
    • Canada
    • South America
    • Europe
    • Western Europe
    • Germany
    • France
    • Italy
    • Spain
    • UK
    • Rest of Western Europe
    • Eastern Europe
    • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
    • Middle East & Africa
    • Middle East
    • Africa
    • Academic institutes and universities
    • Government research institutes
    • Diagnostic laboratories
    • Research and Development (R&D) companies
    • Oncology research institutes
    • Pharmaceutical companies

    Adrenocortical Carcinoma Treatment Market, by Region

    • Americas
    • North America
    • US
    • Canada
    • South America
    • Europe
    • Western Europe
    • Germany
    • France
    • Italy
    • Spain
    • UK
    • Rest of Western Europe
    • Eastern Europe
    • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
    • Middle East & Africa
    • Middle East
    • Africa
    • Academic institutes and universities
    • Government research institutes
    • Diagnostic laboratories
    • Research and Development (R&D) companies
    • Oncology research institutes
    • Pharmaceutical companies

    Adrenocortical Carcinoma Treatment Market Key Players

    • and Digirad Corporation 
    • NeuroLogica Corp.
    • Hitachi, Ltd.
    • Sinovision Technologies (Beijing) CO., Ltd.
    • Fresenius Kabi AG
    • Mylan N.V.
    • WG Critical Care, LLC
    • General Electric Company
    • Bristol-Myers Squibb Company
    • HRA Pharma
    • Orphagen Pharmaceuticals, Inc.
    • Merck & Co.
    • Millendo Therapeutics, Inc.
    • Exelixis, Inc.
    • EnGeneIC Ltd
    • Pfizer Ltd.
    • Arqule

    Adrenocortical Carcinoma Treatment Market, by Therapy

    • Others
    • Adjuvant Therapy
    • Brachytherapy
    • External beam radiation therapy
    • Radiation Therapy
    • Targeted Therapy
    • Chemotherapy
    • Open surgery
    • Laparoscopic surgery
    • Surgery
    • Cancer Research Institutes
    • Ambulatory Surgical Centers
    • Hospitals and Clinics
    • Americas
    • North America
    • US
    • Canada
    • South America
    • Europe
    • Western Europe
    • Germany
    • France
    • Italy
    • Spain
    • UK
    • Rest of Western Europe
    • Eastern Europe
    • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
    • Middle East & Africa
    • Middle East
    • Africa
    • Academic institutes and universities
    • Government research institutes
    • Diagnostic laboratories
    • Research and Development (R&D) companies
    • Oncology research institutes
    • Pharmaceutical companies

    Adrenocortical Carcinoma Treatment Market, by End-User

    • Cancer Research Institutes
    • Ambulatory Surgical Centers
    • Hospitals and Clinics
    • Americas
    • North America
    • US
    • Canada
    • South America
    • Europe
    • Western Europe
    • Germany
    • France
    • Italy
    • Spain
    • UK
    • Rest of Western Europe
    • Eastern Europe
    • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
    • Middle East & Africa
    • Middle East
    • Africa
    • Academic institutes and universities
    • Government research institutes
    • Diagnostic laboratories
    • Research and Development (R&D) companies
    • Oncology research institutes
    • Pharmaceutical companies

    Adrenocortical Carcinoma Treatment Market Regional Analysis

    • Metastatic Adrenocortical Carcinoma
    • Localized Adrenocortical Carcinoma
    • Others
    • Adjuvant Therapy
    • Brachytherapy
    • External beam radiation therapy
    • Radiation Therapy
    • Targeted Therapy
    • Chemotherapy
    • Open surgery
    • Laparoscopic surgery
    • Surgery
    • Cancer Research Institutes
    • Ambulatory Surgical Centers
    • Hospitals and Clinics
    • Americas
    • North America
    • US
    • Canada
    • South America
    • Europe
    • Western Europe
    • Germany
    • France
    • Italy
    • Spain
    • UK
    • Rest of Western Europe
    • Eastern Europe
    • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
    • Middle East & Africa
    • Middle East
    • Africa
    • Academic institutes and universities
    • Government research institutes
    • Diagnostic laboratories
    • Research and Development (R&D) companies
    • Oncology research institutes
    • Pharmaceutical companies

    Report Scope

    Report Attribute/Metric Details
    Market Size 2023 3.65 (USD Billion)
    Market Size 2024 3.82 (USD Billion)
    Market Size 2032 8.17 (USD Billion)
    Compound Annual Growth Rate (CAGR) 2.72 % (2024 - 2032)
    Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    Base Year 2023
    Market Forecast Period 2024 - 2032
    Historical Data 2018-2022
      Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
      Key Vendors  Arqule, Pfizer Ltd., EnGeneIC Ltd, Exelixis, Inc., Millendo Therapeutics, Inc., Merck & Co., Orphagen Pharmaceuticals, Inc., HRA Pharma, Bristol-Myers Squibb Company, General Electric Company, WG Critical Care, LLC, Mylan N.V., Fresenius Kabi AG, Sinovision Technologies (Beijing) CO. Ltd. Hitachi Ltd. NeuroLogica Corp., and Digirad Corporation
      Key Market Opportunities   New product launches and R&D Amongst major key Players
      Key Market Drivers Increase in prevalence rates of rare cancers Increased focus of companies on the treatment of adrenocortical carcinomas

    Market Highlights

    Author

    Rahul Gotadki
    Assistant Manager

    She holds an experience of about 6+ years in market research and business consulting, working under the spectrum of information communication technology, telecommunications and semiconductor domains. aarti conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. her expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.

    Leave a Comment

    Latest Comments

    John Doe
    john@example.com

    This is a great article! Really helped me understand the topic better.

    Posted on July 23, 2025, 10:15 AM
    Jane Smith
    jane@domain.com

    Thanks for sharing this. I’ve bookmarked it for later reference.

    Posted on July 22, 2025, 7:45 PM

    FAQs

    What would be the CAGR for Adrenocortical Carcinoma Treatment market during the forecast period of 2024-2032?

    The CAGR for Adrenocortical Carcinoma Treatment market would be 2.72% during the forecast period.

    What could prevent Adrenocortical Carcinoma Treatment market growth?

    Lack of oncology experts and high risk of local occurrence and different metastatic progress can deter Adrenocortical Carcinoma Treatment market growth.

    What are types discussed in the Adrenocortical Carcinoma Treatment market report?

    The types included in Adrenocortical Carcinoma Treatment market report are localized adrenocortical carcinoma and metastatic adrenocortical carcinoma.

    Which region would dominate the Adrenocortical Carcinoma Treatment market?

    The Americas would dominate the Adrenocortical Carcinoma Treatment market.

    Which region would be the fastest-growing in the Adrenocortical Carcinoma Treatment market?

    The APAC region would dominate Adrenocortical Carcinoma Treatment market in terms of growth rate.

    1. Report Prologue
      1. Chapter 2. Market Introduction
      2. 2.1
      3. Definition
      4. Scope of the Study
        1. Research
        2. Assumptions
        3. Limitations
      5. Objective
      6. Chapter
    2. Research Methodology
      1. Introduction
      2. Primary
      3. Research
      4. Secondary Research
      5. Market
      6. Size Estimation
      7. Chapter
    3. Market Dynamics
      1. Drivers
      2. Restraints
      3. Opportunities
      4. 4.4
      5. Challenges
      6. 4.5
      7. Macroeconomic Indicators
      8. Technology Trends & Assessment
      9. Chapter 5.
      10. Market Factor Analysis
      11. Porter’s Five Forces Analysis
        1. Bargaining
        2. Bargaining Power of Buyers
        3. Threat
        4. Threat of Substitutes
      12. Power of Suppliers
      13. of New Entrants
      14. 5.1.5
      15. Intensity of Rivalry
      16. Value Chain Analysis
      17. Investment
      18. Feasibility Analysis
      19. Pricing Analysis
      20. Chapter 6. Global
    4. Adrenocortical Carcinoma Treatment Market, by Type
      1. Introduction
      2. Localized
      3. Adrenocortical Carcinoma
    5. Market Estimates & Forecast, by Region, 2020–2027
      1. Market
      2. Estimates & Forecast, by Country, 2020–2027
      3. Metastatic Adrenocortical
      4. Carcinoma
      5. Market
      6. Estimates & Forecast, by Region, 2020–2027
      7. Market Estimates & Forecast,
      8. by Country, 2020–2027
      9. Chapter 7. Global Adrenocortical Carcinoma Treatment
    6. Market, by Therapy
      1. 7.1
      2. Introduction
      3. 7.2
      4. Surgery
    7. Laparoscopic surgery
    8. Market Estimates & Forecast, by Region, 2020–2027
      1. Market
      2. Estimates & Forecast, by Country, 2020–2027
      3. Market Estimates & Forecast,
      4. by Region, 2020–2027
    9. Open surgery
    10. Market Estimates & Forecast, by Country, 2020–2027
      1. Chemotherapy
      2. Market Estimates &
      3. Forecast, by Region, 2020–2027
    11. Market Estimates & Forecast, by Country,
      1. 7.4
      2. Targeted Therapy
      3. Market
      4. Estimates & Forecast, by Region, 2020–2027
      5. Market Estimates & Forecast,
      6. by Country, 2020–2027
      7. Radiation Therapy
        1. External beam radiation therapy
      8. Market Estimates & Forecast,
      9. by Region, 2020–2027
    12. Market Estimates & Forecast, by Country, 2020–2027
      1. 7.5.2
      2. Brachytherapy
      3. Market
      4. Estimates & Forecast, by Region, 2020–2027
      5. Market Estimates & Forecast,
      6. by Country, 2020–2027
      7. Adjuvant Therapy
    13. Market Estimates & Forecast, by Region, 2020–2027
      1. Market
      2. Estimates & Forecast, by Country, 2020–2027
      3. Others
    14. Market Estimates & Forecast, by Region, 2020–2027
      1. Market
      2. Estimates & Forecast, by Country, 2020–2027
      3. Chapter 8. Global
    15. Adrenocortical Carcinoma Treatment Market, by End-User
      1. Introduction
      2. Hospitals
      3. and Clinics
      4. Market
      5. Estimates & Forecast, by Region, 2020–2027
    16. Market Estimates & Forecast, by Country, 2020–2027
      1. Ambulatory
      2. Surgical Centers
      3. Market
      4. Estimates & Forecast, by Region, 2020–2027
    17. Market Estimates & Forecast, by Country, 2020–2027
      1. Cancer
      2. Research Institutes
      3. Market
      4. Estimates & Forecast, by Region, 2020–2027
    18. Market Estimates & Forecast, by Country, 2020–2027
      1. Chapter 9.
      2. Global Adrenocortical Carcinoma Treatment, by Region
      3. Introduction
      4. Americas
        1. North
        2. Eastern Europe
      5. America
      6. 9.2.1.1
      7. US
      8. 9.2.1.2
      9. Canada
      10. 9.2.2
      11. South America
      12. 9.3
      13. Europe
      14. 9.3.1
      15. Western Europe
      16. 9.3.1.1
      17. Germany
      18. 9.3.1.2
      19. France
      20. 9.3.1.3
      21. Italy
      22. 9.3.1.4
      23. Spain
      24. 9.3.1.5
      25. UK
      26. 9.3.1.6
      27. Rest of Western Europe
      28. Asia-Pacific
        1. Japan
        2. China
        3. India
        4. Australia
        5. South
      29. Korea
      30. 9.4.6
      31. Rest of Asia-Pacific
      32. Middle East & Africa
        1. Middle East
        2. Africa
      33. Chapter 10.
      34. Company Landscape
      35. Introduction
      36. Market
      37. Share Analysis
      38. Key Development & Strategies
      39. Chapter
    19. Company Profiles
      1. Arqule
        1. Company Overview
        2. Financials Overview
        3. Key
        4. SWOT Analysis
      2. 11.1.2
      3. Product Overview
      4. Developments
      5. Pfizer
        1. Product Overview
        2. Key Developments
      6. Ltd.
      7. 11.2.1
      8. Company Overview
      9. 11.2.3
      10. Financial Overview
      11. 11.2.5
      12. SWOT Analysis
      13. EnGeneIC Ltd
        1. Company Overview
        2. Financial Overview
        3. Key
        4. SWOT Analysis
        5. Product Overview
        6. Key Development
      14. 11.3.2
      15. Product Overview
      16. Development
      17. 11.4
      18. Exelixis, Inc.
      19. 11.4.1
      20. Company Overview
      21. 11.4.3
      22. Financial Overview
      23. 11.4.5
      24. SWOT Analysis
      25. Millendo Therapeutics, Inc.
        1. Company
        2. Product Overview
        3. Financial
        4. Key Developments
        5. SWOT Analysis
      26. Overview
      27. overview
      28. Merck & Co.
        1. Company Overview
        2. Financial Overview
      29. 11.6.2
      30. Product Overview
      31. 11.6.4
      32. Key Developments
      33. 11.6.5
      34. SWOT Analysis
      35. Orphagen Pharmaceuticals,
        1. Product Overview
        2. Financial
        3. Key Developments
        4. SWOT
      36. Inc.
      37. 11.7.1
      38. Overview
      39. Overview
      40. Analysis
      41. HRA Pharma
        1. Overview
        2. Product
        3. Key Developments
        4. SWOT
        5. Overview
        6. Product
        7. Financials
        8. Key
        9. SWOT Analysis
      42. Overview
      43. 11.8.3
      44. Financials
      45. Analysis
      46. 11.9
      47. Bristol-Myers Squibb Company
      48. Overview
      49. Developments
      50. General Electric Company
        1. Overview
        2. Financials
        3. SWOT Analysis
      51. 11.10.2
      52. Product Overview
      53. 11.10.4
      54. Key Developments
      55. WG
        1. Product Overview
        2. Financials
        3. SWOT Analysis
      56. Critical Care, LLC
      57. 11.11.1
      58. Overview
      59. 11.11.4
      60. Key Developments
      61. Mylan
        1. Product Overview
        2. Financials
        3. SWOT Analysis
      62. N.V.
      63. 11.12.1
      64. Overview
      65. 11.12.4
      66. Key Developments
      67. Fresenius
        1. Product Overview
        2. Financials
        3. SWOT Analysis
      68. Kabi AG
      69. 11.13.1
      70. Overview
      71. 11.13.4
      72. Key Developments
      73. SINOVISION
        1. Overview
        2. Product
        3. Financials
        4. Key
        5. SWOT Analysis
      74. Technologies (Beijing)CO., Ltd.
      75. Overview
      76. Developments
      77. Hitachi, Ltd.
        1. Overview
        2. Financials
        3. SWOT Analysis
      78. 11.15.2
      79. Product Overview
      80. 11.15.4
      81. Key Developments
      82. NeuroLogica
        1. Product Overview
        2. Financials
        3. SWOT Analysis
      83. Corp.
      84. 11.16.1
      85. Overview
      86. 11.16.4
      87. Key Developments
      88. Digirad
        1. Product Overview
        2. Financials
        3. SWOT Analysis
      89. Corporation
      90. 11.17.1
      91. Overview
      92. 11.17.4
      93. Key Developments
      94. Chapter 12
      95. MRFR Conclusion
      96. Key Findings
        1. From
        2. Unmet Needs of the Market
      97. CEO’s Viewpoint
      98. 12.2
      99. Key Companies to Watch
      100. Predictions for the Adrenocortical
      101. Carcinoma Treatment Industry
      102. Chapter 13. Appendix
    20. LIST OF TABLES
    21. Global Adrenocortical
      1. Carcinoma Treatment Market Synopsis, 2020–2027
    22. Global Adrenocortical Carcinoma
      1. Treatment Market Estimates and Forecast, 2020–2027 (USD Million)
      2. Table 3
    23. Global Adrenocortical Carcinoma Treatment Market, by Type, 2020–2027
      1. (USD Million)
      2. Table
    24. Global Adrenocortical Carcinoma Treatment Market, by Therapy,
    25. Global Adrenocortical Carcinoma Treatment
    26. Market, by End-User, 2020–2027 (USD Million)
    27. Global
    28. Adrenocortical Carcinoma Treatment Market, by Region, 2020–2027(USD Million)
    29. North
    30. America: Adrenocortical Carcinoma Treatment Market, by Type, 2020–2027 (USD
      1. Million)
    31. North
    32. America: Adrenocortical Carcinoma Treatment Market, by Therapy, 2020–2027
      1. (USD Million)
      2. Table
    33. North America: Adrenocortical Carcinoma Treatment Market, by
      1. End-User, 2020–2027 (USD Million)
    34. North America: Adrenocortical
    35. Carcinoma Treatment Market, by Region, 2020–2027 (USD Million)
    36. US:
    37. Adrenocortical Carcinoma Treatment Market, by Type, 2020–2027 (USD Million)
      1. Table 12
    38. US: Adrenocortical Carcinoma Treatment Market, by Therapy, 2020–2027
      1. (USD Million)
      2. Table
    39. US: Adrenocortical Carcinoma Treatment Market, by End-User,
    40. US: Adrenocortical Carcinoma Treatment Market,
      1. by Region, 2020–2027 (USD Million)
    41. Canada: Adrenocortical Carcinoma
    42. Treatment Market, by Type, 2020–2027 (USD Million)
    43. Canada: Adrenocortical
    44. Carcinoma Treatment Market, by Therapy, 2020–2027 (USD Million)
      1. Table 17
    45. Canada: Adrenocortical Carcinoma Treatment Market, by End-User, 2020–2027
      1. (USD Million)
      2. Table
    46. Canada: Adrenocortical Carcinoma Treatment Market, by Region,
    47. South America: Adrenocortical Carcinoma
    48. Treatment Market, by Type, 2020–2027 (USD Million)
    49. South America: Adrenocortical
    50. Carcinoma Treatment Market, by Therapy, 2020–2027 (USD Million)
      1. Table 21
    51. South America: Adrenocortical Carcinoma Treatment Market, by End-User, 2020–2027
      1. (USD Million)
      2. Table
    52. South America: Adrenocortical Carcinoma Treatment Market, by
      1. Region, 2020–2027 (USD Million)
    53. Europe: Adrenocortical Carcinoma
    54. Treatment Market, by Type, 2020–2027 (USD Million)
    55. Europe: Adrenocortical
    56. Carcinoma Treatment Market, by Therapy, 2020–2027 (USD Million)
      1. Table 25
    57. Europe: Adrenocortical Carcinoma Treatment Market, by End-User, 2020–2027
      1. (USD Million)
      2. Table
    58. Europe: Adrenocortical Carcinoma Treatment Market, by Region,
    59. Western Europe: Adrenocortical Carcinoma
    60. Treatment Market, by Type, 2020–2027 (USD Million)
      1. Table 28
    61. Western Europe: Adrenocortical Carcinoma Treatment Market, by Therapy, 2020–2027
      1. (USD Million)
      2. Table 29
    62. Western Europe: Adrenocortical Carcinoma Treatment Market, by End-User, 2020–2027
      1. (USD Million)
      2. Table
    63. Western Europe: Adrenocortical Carcinoma Treatment Market,
      1. by Region, 2020–2027 (USD Million)
    64. Eastern Europe: Adrenocortical
    65. Carcinoma Treatment Market, by Type, 2020–2027 (USD Million)
    66. Eastern Europe: Adrenocortical Carcinoma
    67. Treatment Market, by Therapy, 2020–2027 (USD Million)
    68. Eastern Europe: Adrenocortical Carcinoma
    69. Treatment Market, by End-User, 2020–2027 (USD Million)
      1. Table 33
    70. Eastern Europe: Adrenocortical Carcinoma Treatment Market, by Region, 2020–2027
      1. (USD Million)
      2. Table
    71. Asia-Pacific: Adrenocortical Carcinoma Treatment Market, by
      1. Type, 2020–2027 (USD Million)
    72. Asia-Pacific: Adrenocortical
    73. Carcinoma Treatment Market, by Therapy, 2020–2027 (USD Million)
      1. Table 34
    74. Asia-Pacific: Adrenocortical Carcinoma Treatment Market, by End-User, 2020–2027
      1. (USD Million)
      2. Table
    75. Asia-Pacific: Adrenocortical Carcinoma Treatment Market, by
      1. Region, 2020–2027 (USD Million)
    76. Middle East & Africa: Adrenocortical
    77. Carcinoma Treatment Market, by Type, 2020–2027 (USD Million)
      1. Table
    78. Middle East & Africa: Adrenocortical Carcinoma Treatment
    79. Market, by Therapy, 2020–2027 (USD Million)
    80. Middle East & Africa:
    81. Adrenocortical Carcinoma Treatment Market, by End-User, 2020–2027 (USD Million)
      1. Table 39
    82. Middle East & Africa: Adrenocortical Carcinoma Treatment Market, by Region,
      1. LIST
    83. OF FIGURES
      1. Figure
    84. Research Process
    85. Segmentation for Global Adrenocortical
      1. Carcinoma Treatment Market
    86. Segmentation Market Dynamics for Global
      1. Adrenocortical Carcinoma Treatment Market
    87. Global Adrenocortical
    88. Carcinoma Treatment Market Share, by Type, 2020 (%)
    89. Global Adrenocortical
    90. Carcinoma Treatment Market Share, by Therapy, 2020 (%)
    91. Global Adrenocortical
    92. Carcinoma Treatment Market Share, by End-User, 2020 (%)
    93. Global Adrenocortical
    94. Carcinoma Treatment Market Share, by Region, 2020 (%)
    95. North America: Adrenocortical
    96. Carcinoma Treatment Market Share, by Country, 2020 (%)
    97. Europe: Adrenocortical
    98. Carcinoma Treatment Market Share, by Country, 2020 (%)
    99. Asia-Pacific: Adrenocortical
    100. Carcinoma Treatment Market Share, by Country, 2020 (%)
    101. Middle East & Africa:
    102. Adrenocortical Carcinoma Treatment Market Share, by Country, 2020 (%)
      1. Figure 12
      2. Global Adrenocortical Carcinoma Treatment Market: Company Share Analysis,
      3. Figure
    103. Arqule: Key Financials
    104. Arqule: Segmental Revenue
      1. Figure 15
      2. Arqule: Geographical Revenue
    105. Pfizer Ltd.: Key Financials
      1. Figure 17
      2. Pfizer Ltd.: Segmental Revenue
    106. Pfizer Ltd.: Geographical Revenue
      1. Figure 19
      2. EnGeneIC Ltd: Key Financials
    107. EnGeneIC Ltd: Segmental Revenue
      1. Figure 21
      2. EnGeneIC Ltd: Geographical Revenue
    108. Exelixis, Inc.: Key Financials
      1. Figure 23
      2. Exelixis, Inc.: Segmental Revenue
    109. Exelixis, Inc.: Geographical
      1. Revenue
      2. Figure
    110. Millendo Therapeutics, Inc.: Key Financials
    111. Millendo
      1. Therapeutics, Inc.: Segmental Revenue
    112. Millendo Therapeutics, Inc.:
      1. Geographical Revenue
      2. Figure
    113. Merck & Co.: Key Financials
    114. Merck & Co.: Segmental
      1. Revenue
      2. Figure
    115. Merck & Co.: Geographical Revenue
      1. Figure 31
      2. Orphagen Pharmaceuticals, Inc.: Key Financials
    116. Orphagen Pharmaceuticals,
      1. Inc.: Segmental Revenue
    117. Orphagen Pharmaceuticals, Inc.: Geographical
      1. Revenue
      2. Figure
    118. HRA Pharma: Key Financials
    119. HRA Pharma: Segmental
      1. Revenue
      2. Figure
    120. HRA Pharma: Geographical Revenue
    121. Bristol-Myers Squibb
      1. Company: Key Financials
    122. Bristol-Myers Squibb Company:
      1. Segmental Revenue
      2. Figure
    123. Bristol-Myers Squibb Company: Geographical Revenue
      1. Figure 40
      2. General Electric Company: Key Financials
    124. General Electric Company:
      1. Segmental Revenue
      2. Figure
    125. General Electric Company: Geographical Revenue
    126. WG
      1. Critical Care, LLC: Key Financials
    127. WG Critical Care, LLC: Segmental
      1. Revenue
      2. Figure
    128. WG Critical Care, LLC: Geographical Revenue
      1. Figure 46
      2. Mylan N.V.: Key Financials
    129. Mylan N.V.: Segmental Revenue
      1. Figure 48
      2. Mylan N.V.: Geographical Revenue
    130. Fresenius Kabi AG: Key
      1. Financials
      2. Figure
    131. Fresenius Kabi AG: Segmental Revenue
    132. Fresenius Kabi AG: Geographical
      1. Revenue
      2. Figure
    133. SINOVISION Technologies (Beijing)CO.,Ltd.: Key Financials
      1. Figure 53
      2. SINOVISION Technologies (Beijing)CO.,Ltd.: Segmental Revenue
    134. SINOVISION
      1. Technologies (Beijing)CO.,Ltd.: Geographical Revenue
    135. Hitachi, Ltd.: Key Financials
      1. Figure 56
      2. Hitachi, Ltd.: Segmental Revenue
    136. Hitachi, Ltd.: Geographical
      1. Revenue
      2. Figure
    137. NeuroLogica Corp.: Key Financials
    138. NeuroLogica Corp.: Segmental
      1. Revenue
      2. Figure
    139. NeuroLogica Corp.: Geographical Revenue
    140. Digirad Corporation:
      1. Key Financials
      2. Figure
    141. Digirad Corporation: Segmental Revenue
    142. Digirad Corporation:
      1. Geographical Revenue

    Adrenocortical Carcinoma Treatment Market Segmentation

    Market Segmentation Overview

    • Detailed segmentation data will be available in the full report
    • Comprehensive analysis by multiple parameters
    • Regional and country-level breakdowns
    • Market size forecasts by segment
    Infographic

    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Get Free Sample

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne

    Founder
    Case Study
    Chemicals and Materials